|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Thromboembolism Therapy Area Pipeline Report
|
Mar 2011 |
£945 |
100% |
Venous Thromboembolism Global Clinical Trials Review
H1, 2012
|
Jan 2012 |
£630 |
99% |
Thromboembolism - Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
98% |
Thromboembolism Global Clinical Trials Review
Q2, 2011
|
May 2011 |
£630 |
98% |
Venous Thromboembolism - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
98% |
Venous Thromboembolism (VTE) Therapeutics
Pipeline Assessment and Market Forecasts to 2018
|
Jan 2012 |
£2,525 |
97% |
Clinical Trial Recruitment in Cardiovascular Diseases
Average Patient Recruitment per Trial Was The Highest in Venous Thromboembolism
|
Sep 2011 |
£2,215 |
93% |
Endpoints - Clinical Trials in Cardiovascular Disorders
Optimal Use of Surrogate Endpoints and Clinical Biomarkers are Key Determinants of Success
|
Jan 2012 |
£2,215 |
91% |
|
Anticoagulants
|
Sep 2010 |
£2,845 |
65% |
|
Disease Management
|
Jan 2004 |
£30 |
63% |
Antithrombotics
Competitor Analysis
|
Jul 2008 |
£415 |
63% |
Dabigatran
Comprehensive patent search
|
Jun 2011 |
£4,150 |
59% |
Rivaroxaban
Comprehensive Patent Search
|
Jun 2011 |
£3,320 |
59% |
Bemiparin sodium
Comprehensive Patent Search
|
Jun 2011 |
£4,775 |
58% |
Fondaparinux sodium
Comprehensive Patent Search
|
Jun 2011 |
£4,150 |
58% |
Enoxaparin sodium
Comprehensive Patent Search
|
Jun 2011 |
£4,565 |
58% |
|
Analysis of the Anticoagulant Market
|
Dec 2011 |
£3,795 |
57% |
Anticoagulants
A Global Market Review
|
Nov 2009 |
£1,895 |
54% |
Financial Markets Research: ASCO Review Part IICO 2006 Annual Meeting
A summary of highlights presented at the ASCO 2006 Annual Meeting
|
Aug 2006 |
£1,390 |
53% |
|
Atrial Fibrillation
|
Aug 2010 |
£2,500 |
52% |
Portola Pharmaceuticals, Inc. – Product Pipeline Review
H2 2011
|
Dec 2011 |
£315 |
52% |
Rivaroxaban - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
51% |
Bemiparin sodium - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
50% |
Fondaparinux sodium - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
50% |
Enoxaparin sodium - Key patent, SPC, and data exclusivity expiry (7 country coverage)
Pipeline Selector Core
|
Jun 2011 |
£310 |
50% |
|
Commercializing Biomarkers in Therapeutic and Diagnostic Applications
|
May 2011 |
£2,020 |
48% |
Rivaroxaban - Key patent, SPC, and data exclusivity expiry (44 countries coverage)
Pipeline Selector Extended
|
Jun 2011 |
£705 |
48% |
Bemiparin sodium - Key patent, SPC, and data exclusivity expiry (44 countries coverage)
Pipeline Selector Extended
|
Jun 2011 |
£705 |
47% |
Fondaparinux sodium - Key patent, SPC, and data exclusivity expiry (44 countries coverage)
Pipeline Selector Extended
|
Jun 2011 |
£705 |
47% |
Enoxaparin sodium - Key patent, SPC, and data exclusivity expiry (44 countries coverage)
Pipeline Selector Extended
|
Jun 2011 |
£705 |
47% |
